SonoThera
Summary active Updated Jun 3, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
Founders
About
SonoThera is a clinical-stage biotechnology company developing ultrasound-mediated nonviral genetic medicines 1 2. The company’s platform combines RIPPLE, a proprietary ultrasound-mediated delivery technology, with PORE, a payload engineering platform supporting DNA and RNA therapeutics, gene editing, and gene silencing 1 3. SonoThera’s approach uses widely available, FDA-cleared diagnostic ultrasound systems for noninvasive outpatient procedures, with the goal of safe, targeted, and repeatable delivery of genetic medicines 1. Lead programs target Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD), with first clinical trials expected to begin in 2027 1 2.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-06-10 | Series B | $125M | Vida Ventures | ARK Invest, CureDuchenne Ventures, Leaps by Bayer, Otsuka Pharmaceutical, SymBiosis, UCB Ventures, Vivo Capital, ARCH Venture Partners, Alexandria Venture Investments, Duquesne Family Office, Illumina Ventures, Johnson & Johnson Innovation - JJDC, Medical Excellence Capital, RA Capital, Vertex Ventures HC 1 2 3 |
The Series B was oversubscribed 1. In conjunction with the financing, Rajul Jain, M.D. (Managing Director, Vida Ventures) and Rakhshita Dhar, M.S. (Vice President & Head, Healthcare Venture Investments at Leaps by Bayer) joined SonoThera’s Board of Directors 1.
What Investors Say
No independently sourced investor quotes found for this round at time of profile creation.
What Founders Say
CEO Kenneth Greenberg stated that the platform “could allow the application of gene therapy into chronic prevalent diseases with much greater populations than rare disease[s]” 3. On the payload capacity advantage over viral vectors, Greenberg said: “It’s over a 13-kilobase payload, which is essentially about three times larger than you can fit into an AAV vector” 3. On the DMD program, Greenberg said: “We’re not aware of any other company that’s attempting to deliver full-length dystrophin” 3.
Sources
-
BusinessWire, “SonoThera Closes Oversubscribed $125 Million Series B Financing to Advance Clinical Development of Ultrasound-Mediated Nonviral Genetic Medicines,” June 10, 2026. Accessed June 2026. https://www.businesswire.com/news/home/20260610731032/en/SonoThera-Closes-Oversubscribed-$125-Million-Series-B-Financing-to-Advance-Clinical-Development-of-Ultrasound-Mediated-Nonviral-Genetic-Medicines↩↩↩↩↩↩↩
-
BioSpace, “SonoThera Closes Oversubscribed $125 Million Series B Financing to Advance Clinical Development of Ultrasound-Mediated Nonviral Genetic Medicines,” June 10, 2026. Accessed June 2026. https://www.biospace.com/press-releases/sonothera-closes-oversubscribed-125-million-series-b-financing-to-advance-clinical-development-of-ultrasound-mediated-nonviral-genetic-medicines↩↩↩
-
FierceBiotech, “Big Pharma-backed SonoThera sounds off with $125M series B for bubble-based genetic delivery,” June 10, 2026. Accessed June 2026. https://www.fiercebiotech.com/biotech/big-pharma-backed-sonothera-sounds-125m-series-b-bubble-based-genetic-delivery↩↩↩↩↩